Full Text Journal Articles by
Author J Michael Bishop


Find full text journal articles

The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.

Vikash J Bhagwandin, J Michael Bishop, Woodring E Wright, Jerry W Shay,

Cancer stem cells (CSCs) typically have the capacity to evade chemotherapy and may be the principal source of metastases. CSCs for human pancreatic ductal carcinoma (PDAC) have been identified, but neither the metastatic potential nor the chemoresistance of these cells has been adequately evaluated. We have addressed these issues by ... Read more >>

PLoS ONE (PloS one)
[2016, 11(2):e0148807]

Cited: 16 times

View full text PDF listing >>

Monocytes promote liver carcinogenesis in an oncogene-specific manner.

Vladislava Juric, Brian Ruffell, Kimberley J Evason, Junjie Hu, Li Che, Linlin Wang, Xin Chen, J Michael Bishop,

The leukocyte composition of tumors is heterogeneous, as is the involvement of each leukocyte subset in promoting or restraining tumorigenesis. This heterogeneity reflects the tissue of origin, tumor stage, and the functional state of leukocyte activation, but its biological roots remain poorly understood. Since tumorigenesis is driven by various genetic ... Read more >>

J. Hepatol. (Journal of Hepatology)
[2016, 64(4):881-890]

Cited: 5 times

View full text PDF listing >>


Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma.

Jinyu Li, Maia Chanrion, Eric Sawey, Tim Wang, Edward Chow, Aaron Tward, Yi Su, Wen Xue, Robert Lucito, Lars Zender, Scott W Lowe, J Michael Bishop, Scott Powers,

Genomic analysis of human hepatocellular carcinoma (HCC) is potentially confounded by the differentiation state of the hepatic cell-of-origin. Here we integrated genomic analysis of mouse HCC (with defined cell-of-origin) along with normal development. We found a major shift in expression of Wnt and RXR-α pathway genes (up and down, respectively) ... Read more >>

PLoS ONE (PloS one)
[2015, 10(3):e0118480]

Cited: 8 times

View full text PDF listing >>

Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma.

Kathleen M Capaccione, Xuehui Hong, Katherine M Morgan, Wenyu Liu, J Michael Bishop, LianXin Liu, Elke Markert, Malik Deen, Christine Minerowicz, Joseph R Bertino, Thaddeus Allen, Sharon R Pine,

Sox9 has gained increasing importance both functionally and as a prognostic factor in cancer. We demonstrate a functional role for Sox9 in inducing a mesenchymal phenotype in lung ADC. We show that Sox9 mRNA and protein are overexpressed in lung ADC, particularly those with KRAS mutations. Sox9 expression correlated with ... Read more >>

Oncotarget (Oncotarget)
[2014, 5(11):3636-3650]

Cited: 33 times

View full text PDF listing >>

Nucleostemin maintains self-renewal of embryonic stem cells and promotes reprogramming of somatic cells to pluripotency.

Jian Qu, J Michael Bishop,

Nucleostemin (NS) is a nucleolar GTP-binding protein that was first identified in neural stem cells, the functions of which remain poorly understood. Here, we report that NS is required for mouse embryogenesis to reach blastulation, maintenance of embryonic stem cell (ESC) self-renewal, and mammary epithelial cell (MEC) reprogramming to induced ... Read more >>

J. Cell Biol. (The Journal of Cell Biology)
[2012, 197(6):731-745]

Cited: 29 times

View full text PDF listing >>

MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits.

Hong Liu, Derek C Radisky, Dun Yang, Ren Xu, Evette S Radisky, Mina J Bissell, J Michael Bishop,

Overexpression of MYC transforms cells in culture, elicits malignant tumours in experimental animals and is found in many human tumours. We now report the paradoxical finding that this powerful oncogene can also act as a suppressor of cell motility, invasiveness and metastasis. Overexpression of MYC stimulated proliferation of breast cancer ... Read more >>

Nat. Cell Biol. (Nature cell biology)
[2012, 14(6):567-574]

Cited: 105 times

View full text PDF listing >>

Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells.

Edward Kai-Hua Chow, Ling-ling Fan, Xin Chen, J Michael Bishop,

At least some cancer stem cells (CSCs) display intrinsic drug resistance that may thwart eradication of a malignancy by chemotherapy. We explored the genesis of such resistance by studying mouse models of liver cancer driven by either MYC or the combination of oncogenic forms of activation of v-akt murine thymoma ... Read more >>

Hepatology (Hepatology (Baltimore, Md.))
[2012, 56(4):1331-1341]

Cited: 39 times

View full text PDF listing >>

Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.

Thaddeus D Allen, Elena M Rodriguez, Kirk D Jones, J Michael Bishop,

Notch1 encodes the canonical member of the mammalian Notch receptor family. Activating lesions frequently affect Notch1 in T-cell acute lymphoblastic leukemia (T-ALL) and, recently, have been found in non-small-cell lung cancer (NSCLC) as well. We explored the oncogenic potential of activated Notch1 in the lung by developing a transgenic mouse ... Read more >>

Cancer Res. (Cancer research)
[2011, 71(18):6010-6018]

Cited: 58 times

View full text PDF listing >>

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Mariia O Yuneva, Teresa W M Fan, Thaddeus D Allen, Richard M Higashi, Dana V Ferraris, Takashi Tsukamoto, José M Matés, Francisco J Alonso, Chunmei Wang, Youngho Seo, Xin Chen, J Michael Bishop,

The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to ... Read more >>

Cell Metab. (Cell metabolism)
[2012, 15(2):157-170]

Cited: 241 times

View full text PDF listing >>

Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development.

Radhika Nair, Simon Junankar, Sandra O'Toole, Jaynish Shah, Alexander D Borowsky, J Michael Bishop, Alexander Swarbrick,

The accumulation of poorly differentiated cells is a hallmark of breast neoplasia and progression. Thus an understanding of the factors controlling mammary differentiation is critical to a proper understanding of breast tumourigenesis. The Inhibitor of Differentiation 1 (Id1) protein has well documented roles in the control of mammary epithelial differentiation ... Read more >>

PLoS ONE (PloS one)
[2010, 5(8):e11947]

Cited: 8 times

View full text PDF listing >>

A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter.

Susan L Woods, J Michael Bishop,

We have generated a novel transgenic mouse to direct inducible and reversible transgene expression in the melanocytic compartment. The Dopachrome tautomerase (Dct) control sequences we used are active early in the development of melanocytes and so this system was designed to enable the manipulation of transgene expression during development in ... Read more >>

Transgenic Res. (Transgenic research)
[2011, 20(2):421-428]

Cited: 6 times

View full text PDF listing >>

Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response.

Alexander Swarbrick, Emie Roy, Thaddeus Allen, J Michael Bishop,

Recent evidence demonstrates that senescence acts as a barrier to tumorigenesis in response to oncogene activation. Using a mouse model of breast cancer, we tested the importance of the senescence response in solid cancer and identified genetic pathways regulating this response. Mammary expression of activated Ras led to the formation ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2008, 105(14):5402-5407]

Cited: 62 times

View full text PDF listing >>

Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.

Kenneth A Field, Soratree Charoenthongtrakul, J Michael Bishop, Yosef Refaeli,

We have used a mouse model based on overexpression of c-Myc in B cells genetically engineered to be self-reactive to test the hypothesis that farnesyl transferase inhibitors (FTIs) can effectively treat mature B cell lymphomas. FTIs are undergoing clinical trials to treat both lymphoid and non-lymphoid malignancies and we wished ... Read more >>

Mol. Cancer (Molecular cancer)
[2008, 7:39]

Cited: 4 times

View full text PDF listing >>

Distinct pathways of genomic progression to benign and malignant tumors of the liver.

Aaron D Tward, Kirk D Jones, Stephen Yant, Siu Tim Cheung, Sheung Tat Fan, Xin Chen, Mark A Kay, Rong Wang, J Michael Bishop,

We used several of the genetic lesions commonly associated with human liver tumors to reconstruct genetic progression to hepatocellular carcinoma and adenoma in mouse models. We initiated tumorigenesis with a transgene of the protooncogene MET or by hydrodynamic transfection of MET in combination with other genes into the livers of ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2007, 104(37):14771-14776]

Cited: 99 times

View full text PDF listing >>

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.

Andrei Goga, Dun Yang, Aaron D Tward, David O Morgan, J Michael Bishop,

Tumor cells have a dysregulated cell cycle that may render their proliferation especially sensitive to the inhibition of cyclin-dependent kinases (CDKs), important regulators of cell cycle progression. We examined the effects of CDK1 inhibition in the context of different oncogenic signals. Cells transformed with MYC, but not cells transformed by ... Read more >>

Nat. Med. (Nature medicine)
[2007, 13(7):820-827]

Cited: 159 times

View full text PDF listing >>

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.

Alana L Welm, Julie B Sneddon, Carmen Taylor, Dimitry S A Nuyten, Marc J van de Vijver, Bruce H Hasegawa, J Michael Bishop,

A better understanding of tumor metastasis requires development of animal models that authentically reproduce the metastatic process. By modifying an existing mouse model of breast cancer, we discovered that macrophage-stimulating protein promoted breast tumor growth and metastasis to several organs. A special feature of our findings was the occurrence of ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2007, 104(18):7570-7575]

Cited: 80 times

View full text PDF listing >>

MET and MYC cooperate in mammary tumorigenesis.

Alana L Welm, Suwon Kim, Bryan E Welm, J Michael Bishop,

In human breast cancer, overexpression of the protooncogene MET is strongly associated with poor prognosis and high risk of metastasis. It stands out as a reliable prognostic indicator of survival and defines a set of tumors exclusive of those that express HER2 or hormone receptors. Studies have shown that overexpression ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2005, 102(12):4324-4329]

Cited: 56 times

View full text PDF listing >>

Re-aim blame for NIH's hard times.

J Michael Bishop, Harold Varmus,

Science (Science (New York, N.Y.))
[2006, 312(5773):499]

Cited: 6 times

View full text PDF listing >>

Mary Lasker and her prizes: an appreciation.

J Michael Bishop,

[2005, 294(11):1418-1419]

Cited: 0 times

View full text PDF listing >>

The protooncogene MYC can break B cell tolerance.

Yosef Refaeli, Kenneth A Field, Brian C Turner, Andreas Trumpp, J Michael Bishop,

The protooncogene MYC has been implicated in both the proliferation and programmed cell death of lymphoid cells, and in the genesis of lymphoid tumors. Here, we report that overexpression of MYC, as found in many lymphomas, can break immune tolerance. Mice that would otherwise be tolerant to a transgenic autoantigen ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2005, 102(11):4097-4102]

Cited: 17 times

View full text PDF listing >>

Cell division and cell survival in the absence of survivin.

Dun Yang, Alana Welm, J Michael Bishop,

The survivin protein contains structural features of the inhibitor of apoptosis protein family. Previous studies have suggested that survivin is essential for cell survival because it counteracts an otherwise constitutive propensity to apoptosis during mitosis. In addition, survivin appears to be a component of the chromosomal passenger protein complex that ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2004, 101(42):15100-15105]

Cited: 103 times

View full text PDF listing >>

Negative control of the Myc protein by the stress-responsive kinase Pak2.

Zhongdong Huang, Jolinda A Traugh, J Michael Bishop,

Pak2 is a serine/threonine kinase that participates in the cellular response to stress. Among the potential substrates for Pak2 is the protein Myc, encoded by the proto-oncogene MYC. Here we demonstrate that Pak2 phosphorylates Myc at three sites (T358, S373, and T400) and affects Myc functions both in vitro and ... Read more >>

Mol. Cell. Biol. (Molecular and cellular biology)
[2004, 24(4):1582-1594]

Cited: 39 times

View full text PDF listing >>

A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer.

Suwon Kim, Koei Chin, Joe W Gray, J Michael Bishop,

We have devised a screen for genes that suppress the loss of contact inhibition elicited by overexpression of the protooncogene MYCN. The initial application of this screen detected nine distinctive suppressors within a representative human cDNA library. One of these genes was ING4, a potential tumor suppressor gene that maps ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2004, 101(46):16251-16256]

Cited: 81 times

View full text PDF listing >>

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Catherine M Shachaf, Andrew M Kopelman, Constadina Arvanitis, Asa Karlsson, Shelly Beer, Stefanie Mandl, Michael H Bachmann, Alexander D Borowsky, Boris Ruebner, Robert D Cardiff, Qiwei Yang, J Michael Bishop, Christopher H Contag, Dean W Felsher,

Hepatocellular carcinoma is generally refractory to clinical treatment. Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with ... Read more >>

Nature (Nature)
[2004, 431(7012):1112-1117]

Cited: 437 times

View full text PDF listing >>

RNA interference (RNAi) with RNase III-prepared siRNAs.

Dun Yang, Andrei Goga, J Michael Bishop,

Small interfering RNA (siRNA) has become a powerful tool for selectively silencing gene expression in cultured mammalian cells. Because different siRNAs of the same gene have varying silencing capacities, several different siRNAS typically must be screened to obtain a region that will effectively silence the gene of interest. However, RNA ... Read more >>

Methods Mol. Biol. (Methods in molecular biology (Clifton, N.J.))
[2004, 252:471-482]

Cited: 14 times

View full text PDF listing >>


1.0807 s